Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESR1 | P03372 | 10/20 | 0.53 |
| ▸ | ESR2 | Q92731 | 6/20 | 0.53 |
| ▸ | ABL1 | P00519 | 1/20 | 0.45 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.45 |
| ▸ | BCR | P11274 | 1/20 | 0.45 |
| ▸ | APP | P05067 | 3/20 | 0.45 |
| ▸ | CYP2C19 | P33261 | 3/20 | 0.45 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.45 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.45 |
| ▸ | RPS6KA3 | P51812 | 2/20 | 0.44 |
| ▸ | KIF11 | P52732 | 1/20 | 0.44 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.44 |
| ▸ | USP7 | Q93009 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27928527 | 0.95 | ESR1 (0.57) | ESR1ESR2ABL1ABCB1BCR | |
| SCHEMBL27595071 | 0.83 | USP7 (0.47) | ESR1ESR2ABL1ABCB1BCR | |
| SCHEMBL28226426 | 0.81 | ESR1 (0.70) | ESR1ESR2APPCYP2C19CYP2C9 | |
| SCHEMBL38659424 | 0.81 | ESR1 (0.70) | ESR1ESR2APPCYP2C19CYP2C9 | |
| SCHEMBL1759436 | 0.80 | ESR2 (0.47) | ESR1ESR2ABL1ABCB1BCR | |
| SCHEMBL1759486 | 0.80 | ESR1 (0.46) | ESR1ESR2ABL1ABCB1BCR | |
| SCHEMBL28901881 | 0.80 | ESR1 (0.53) | ESR1ESR2APPCYP2C19CYP2C9 | |
| SCHEMBL9858166 | 0.79 | ESR1 (0.57) | ESR1ESR2APPCYP2C19CYP2C9 | |
| SCHEMBL29901376 | 0.79 | ESR1 (0.57) | ESR1ESR2APPCYP2C19CYP2C9 | |
| SCHEMBL22002470 | 0.79 | ESR1 (0.43) | ESR1ESR2APPCYP2C19CYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-110088077-A | (meth) acrylate compound, optical resin additive, optical element, and optical device | 株式会社尼康 | 2019-08-02 | — | — | CN | disclosed |
| WO-2011067174-A1 | ANILINE ANALOGS AS GLYCOGEN SYNTHASE ACTIVATORS | F. HOFFMANN-LA ROCHE AG (CH) | 2011-06-09 | — | — | WO | disclosed |
| WO-2011067174-A1 | ANILINE ANALOGS AS GLYCOGEN SYNTHASE ACTIVATORS | F. HOFFMANN-LA ROCHE AG (CH) | 2011-06-09 | — | — | WO | disclosed |
| WO-2011067266-A1 | CARBOXYLIC ACID ANALOGS AS GLYCOGEN SYNTHASE ACTIVATORS | F. HOFFMANN-LA ROCHE AG (CH) | 2011-06-09 | — | — | WO | disclosed |
| WO-2011067266-A1 | CARBOXYLIC ACID ANALOGS AS GLYCOGEN SYNTHASE ACTIVATORS | F. HOFFMANN-LA ROCHE AG (CH) | 2011-06-09 | — | — | WO | disclosed |
| US-20110136792-A1 | NOVEL CARBOXYLIC ACID ANALOGS AS GLYCOGEN SYNTHASE ACTIVATORS | BOLIN DAVID ROBERT | 2011-06-09 | — | — | US | disclosed |
| US-20110136792-A1 | NOVEL CARBOXYLIC ACID ANALOGS AS GLYCOGEN SYNTHASE ACTIVATORS | BOLIN DAVID ROBERT | 2011-06-09 | — | — | US | disclosed |
| US-20110136792-A1 | NOVEL CARBOXYLIC ACID ANALOGS AS GLYCOGEN SYNTHASE ACTIVATORS | BOLIN DAVID ROBERT | 2011-06-09 | — | — | US | disclosed |
| US-20110130438-A1 | ANILINE ANALOGS AS GLYCOGEN SYNTHASE ACTIVATORS | BOLIN DAVID ROBERT | 2011-06-02 | — | — | US | disclosed |
| US-20110130438-A1 | ANILINE ANALOGS AS GLYCOGEN SYNTHASE ACTIVATORS | BOLIN DAVID ROBERT | 2011-06-02 | — | — | US | disclosed |
| US-20110112161-A1 | INDOLE AND INDAZOLE ANALOGS AS GLYCOGEN SYNTHASE ACTIVATORS | BOLIN DAVID ROBERT | 2011-05-12 | — | — | US | disclosed |
| US-20110112158-A1 | BENZISOXAZOLE ANALOGS AS GLYCOGEN SYNTHASE ACTIVATORS | BOLIN DAVID ROBERT | 2011-05-12 | — | — | US | disclosed |
| US-20110112161-A1 | INDOLE AND INDAZOLE ANALOGS AS GLYCOGEN SYNTHASE ACTIVATORS | BOLIN DAVID ROBERT | 2011-05-12 | — | — | US | disclosed |
| US-20110112158-A1 | BENZISOXAZOLE ANALOGS AS GLYCOGEN SYNTHASE ACTIVATORS | BOLIN DAVID ROBERT | 2011-05-12 | — | — | US | disclosed |
| US-20110112161-A1 | INDOLE AND INDAZOLE ANALOGS AS GLYCOGEN SYNTHASE ACTIVATORS | BOLIN DAVID ROBERT | 2011-05-12 | — | — | US | disclosed |
| US-20110112147-A1 | INDAZOLONE ANALOGS AS GLYCOGEN SYNTHASE ACTIVATORS | BOLIN DAVID ROBERT | 2011-05-12 | — | — | US | disclosed |
| US-20110112158-A1 | BENZISOXAZOLE ANALOGS AS GLYCOGEN SYNTHASE ACTIVATORS | BOLIN DAVID ROBERT | 2011-05-12 | — | — | US | disclosed |
| US-7939569-B1 | Aniline analogs as glycogen synthase activators | HOFFMANN-LA ROCHE INC. (US) | 2011-05-10 | — | — | US | disclosed |
| US-7939569-B1 | Aniline analogs as glycogen synthase activators | HOFFMANN-LA ROCHE INC. (US) | 2011-05-10 | — | — | US | disclosed |
| US-7939569-B1 | Aniline analogs as glycogen synthase activators | HOFFMANN-LA ROCHE INC. (US) | 2011-05-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110112161-A1 | INDOLE AND INDAZOLE ANALOGS AS GLYCOGEN SYNTHASE ACTIVATORS | GYS2, PYGL, GSK3B | ESR1 2982/4885ESR2 1250/4885ABL1 1520/4885 |
| US-20110136792-A1 | NOVEL CARBOXYLIC ACID ANALOGS AS GLYCOGEN SYNTHASE ACTIVATORS | GYS2, GYS1, PYGL | ESR1 1761/4885ESR2 827/4885ABL1 4268/4885 |
| US-20110130438-A1 | ANILINE ANALOGS AS GLYCOGEN SYNTHASE ACTIVATORS | GYS2, PYGL, GYS1 | ESR1 2277/4885ESR2 658/4885ABL1 2703/4885 |
| US-20110112158-A1 | BENZISOXAZOLE ANALOGS AS GLYCOGEN SYNTHASE ACTIVATORS | GYS2, GYS1, PYGL | ESR1 2879/4885ESR2 1148/4885ABL1 3140/4885 |
| US-20110112147-A1 | INDAZOLONE ANALOGS AS GLYCOGEN SYNTHASE ACTIVATORS | GYS2, GYS1, PYGL | ESR1 2879/4885ESR2 973/4885ABL1 1782/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.